Current Problems in Cardiology最新文献

{"title":"Information for Readers","authors":"","doi":"10.1016/S0146-2806(25)00083-0","DOIUrl":"10.1016/S0146-2806(25)00083-0","url":null,"abstract":"","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"50 6","pages":"Article 103061"},"PeriodicalIF":3.0,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143887492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editor’s Message","authors":"","doi":"10.1016/S0146-2806(25)00088-X","DOIUrl":"10.1016/S0146-2806(25)00088-X","url":null,"abstract":"","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"50 6","pages":"Article 103066"},"PeriodicalIF":3.0,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143887489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Title Page","authors":"","doi":"10.1016/S0146-2806(25)00082-9","DOIUrl":"10.1016/S0146-2806(25)00082-9","url":null,"abstract":"","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"50 6","pages":"Article 103060"},"PeriodicalIF":3.0,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143887488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guidelines for Authors","authors":"","doi":"10.1016/S0146-2806(25)00087-8","DOIUrl":"10.1016/S0146-2806(25)00087-8","url":null,"abstract":"","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"50 6","pages":"Article 103065"},"PeriodicalIF":3.0,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143887490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Testosterone therapy in patients with heart failure and protein-calorie malnutrition: Insights from a propensity-matched cohort study","authors":"SilvioNunes Augusto Jr. ,&nbsp;David C. Kaelber MD PhD MPH ,&nbsp;W.H. Wilson Tang MD","doi":"10.1016/j.cpcardiol.2025.103070","DOIUrl":"10.1016/j.cpcardiol.2025.103070","url":null,"abstract":"<div><h3>Introduction</h3><div>Testosterone therapy may improve physical capacity and mood in men with chronic heart failure. However, recent findings have raised concerns that testosterone therapy could also increase the risk of atrial fibrillation, pulmonary embolism, and acute kidney injury.</div></div><div><h3>Methods</h3><div>Leveraging data from the TriNetX platform from January 1, 2014, to December 01, 2024, we conducted a propensity-matched analysis of two cohorts of patients with heart failure with protein-calorie malnutrition, where the only difference between cohorts was testosterone therapy. The primary outcomes were all-cause mortality and the incidence of acute heart failure, with secondary outcomes including major adverse cardiovascular events as well as cardiovascular, kidney, and thrombotic diseases.</div></div><div><h3>Results</h3><div>After propensity matching, 577 patients were compared across the two cohorts. The findings indicated that testosterone therapy reduced the risk of all-cause mortality (hazard ratio [HR] 0.56, 95 % confidence interval [CI] 0.46–0.68), acute heart failure (HR 0.62, 95 % CI 0.49–0.78), and major adverse cardiovascular events (HR 0.77, 95 % CI 0.61–0.97). Additionally, incident peripheral arterial disease (HR 0.52, 95 % CI 0.30–0.91), coronary arterial disease (HR 0.83, 95 % CI 0.69–1.00), acute myocardial infarction (HR 0.65, 95 % CI 0.48–0.89), and atrial fibrillation (HR 0.79, 95 % CI 0.66–0.95) also favored the testosterone-treated cohort. There was a trend toward an increased risk of venous thromboembolism (HR 1.14, 95 % CI 1.03–1.27) and stroke (HR 1.12, 95 % CI 0.81–1.54) associated with testosterone therapy.</div></div><div><h3>Conclusion</h3><div>These hypothesis-generating findings support potential beneficial effects of testosterone therapy in patients with heart failure and protein-calorie malnutrition.</div></div>","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"50 7","pages":"Article 103070"},"PeriodicalIF":3.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143912270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diversity is essential in cardiovascular medicine and subspecialties: A comprehensive report of gender, racial, and ethnic representation among cardiovascular fellows from 2005 to 2022","authors":"Omar Obeidat ,&nbsp;Mohammad Tarawneh ,&nbsp;Saeed Abughazaleh ,&nbsp;Nausheen Akhter ,&nbsp;Ann Tong","doi":"10.1016/j.cpcardiol.2025.103067","DOIUrl":"10.1016/j.cpcardiol.2025.103067","url":null,"abstract":"<div><h3>Introduction</h3><div>The diversity of the healthcare workforce is essential for equitable and effective patient care. This comprehensive report analyzes the representation trends among cardiovascular fellows in the US over an 18-year period, focusing on gender, racial, and ethnic representation.</div></div><div><h3>Methods</h3><div>Utilizing data from the National Graduate Medical Education Census, this study analyzes trends in representation across gender, race, and ethnicity among cardiovascular medicine fellows. It examines the expansion of cardiology programs and fellow positions in specialties, assessing the evolution of diversity between 2005 and 2022 using J point trend analysis software.</div></div><div><h3>Results</h3><div>The analysis highlights a stark gender disparity with women comprising only 22 % of fellows, this percentage is even lower in subspecialties. Racial and ethnic disparities are also evident, with Black and Hispanic cardiologists significantly underrepresented, comprising only 12.8 % of cardiac fellows in 2021, even though these groups form 31.9 % of the U.S. population. However, a slow but positive trend toward diversity is noted, with female and Black fellows' representation in cardiology on the rise with AAPC of 5.1 and 3.9, respectively.</div></div><div><h3>Conclusion</h3><div>Our analysis revealed continued racial and gender disparities in the cardiology specialty. This report calls for concerted efforts from academic institutions, healthcare organizations, and policymakers to implement effective strategies for diversity and inclusion, reflecting the aim of creating a workforce that mirrors the diversity of the population it serves.</div></div>","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"50 7","pages":"Article 103067"},"PeriodicalIF":3.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143924222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-implantation syndrome in patients undergoing thoracic and abdominal endovascular aortic repair: Comprehensive systematic review and meta-analysis","authors":"Andreina Carbone MD ,&nbsp;Davide Turchino MD ,&nbsp;Carlo Fanti MD ,&nbsp;Roberta Bottino MD ,&nbsp;Francesco Ferrara MD, PhD ,&nbsp;Carlo Mannina MD ,&nbsp;Stamatios Lerakis MD ,&nbsp;Giuseppe Comentale MD, PhD ,&nbsp;Salvatore Rega MD ,&nbsp;Antonio Cittadini MD, PhD ,&nbsp;Giovanni Esposito MD, PhD ,&nbsp;Emanuele Pilato MD, PhD ,&nbsp;Umberto Marcello Bracale MD, PhD ,&nbsp;Eduardo Bossone MD, PhD","doi":"10.1016/j.cpcardiol.2025.103055","DOIUrl":"10.1016/j.cpcardiol.2025.103055","url":null,"abstract":"<div><div>Post-implantation syndrome (PIS) can lead to prolonged hospitalization and major adverse cardiovascular events (MACE). This systematic review and meta-analysis investigated the clinical profile of PIS after abdominal (EVAR) and thoracic endovascular aortic repair (TEVAR).</div><div>A comprehensive literature search identified 1463 studies, of which 16 (14 retrospective and 2 prospective) met the inclusion criteria. Data from these studies were aggregated using a random effects model to calculate pooled risk ratios and mean differences. The analysis included 2890 patients (males 84.7%, mean age 63.3 years ± 18.8) with 882 experiencing PIS. No significant differences were found in demographics, anthropometric measurements, risk factors, medical history, or chronic medical treatments between the two groups. Fever (above 38°C) was the most frequent clinical manifestation, observed in 75-100% of PIS cases. As expected, higher levels of post-procedural white blood cells (WBC) and platelets (PLT) were shown in PIS patients compared to non-PIS patients. Interestingly, pre-procedural WBC and PLT counts were significantly higher in the PIS group (p&lt;0.001 and p&lt;0.002 respectively). Patients with PIS were more likely to receive polyester graft (p=0.003), while those with polytetrafluoroethylene prostheses were less likely to develop PIS (p=0.04). The PIS group exhibited longer hospital stays compared to the non-PIS group (p&lt;0.001). While most studies reported no evident PIS impact on outcomes, two studies reported higher rate of MACE. Larger prospective studies are needed to determine the optimal management strategies of patients at risk of PIS.</div></div>","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"50 6","pages":"Article 103055"},"PeriodicalIF":3.0,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143847671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RNA-targeting therapies for amyloid transthyretin cardiomyopathy: A systematic review and meta-analysis","authors":"João Victor de Oliveira Ramos ,&nbsp;João Vitor Andrade Fernandes ,&nbsp;Yan Gadelha de Abrantes Formiga ,&nbsp;Fabyan Esberard de Lima Beltrão ,&nbsp;Marcelo Dantas Tavares de Melo ,&nbsp;Fábio Fernandes","doi":"10.1016/j.cpcardiol.2025.103057","DOIUrl":"10.1016/j.cpcardiol.2025.103057","url":null,"abstract":"<div><h3>Introduction</h3><div>Amyloid transthyretin (TTR) cardiomyopathy is a progressive disease caused by TTR amyloid deposition, leading to heart failure and mortality. RNA interference (RNAi) therapies reduce amyloid formation by silencing hepatic TTR mRNA. This meta-analysis evaluates their efficacy and safety.</div></div><div><h3>Methods</h3><div>A systematic search conducted in February 2025 in Cochrane Central, PubMed, and Embase identified RCTs comparing RNAi therapies with placebo. Primary outcomes were all-cause mortality and cardiac adverse events. Safety outcomes included any adverse events and serious cardiac adverse events. A leave-one-out sensitivity analysis assessed robustness. Statistical analyses used inverse-variance common-effects and DerSimonian-Laird random-effects models. Heterogeneity was evaluated using REML and I² statistics, with 95 % confidence intervals (CI).</div></div><div><h3>Results</h3><div>Three RCTs (1,199 patients) met inclusion criteria. RNAi therapy did not significantly reduce all-cause mortality (OR 0.97; 95 % CI 0.26–3.62; I² 72.4 %). However, excluding the ENDEAVOR trial, mortality reduction was significant (OR 0.65; 95 % CI 0.45–0.95; I² 0 %). RNAi therapy reduced cardiac adverse events in pooled (OR 0.72; 95 % CI 0.57–0.90; I² 38 %) and subgroup analyses (OR 0.66; 95 % CI 0.51–0.84; I² 0 %). No significant differences were found in serious cardiac adverse events (OR 0.98; 95 % CI 0.77–1.27; I² 0 %). Safety analyses showed no increase in overall adverse events (OR 0.78; 95 % CI 0.42–1.44; I² 49.8 %).</div></div><div><h3>Conclusion</h3><div>RNAi therapies reduce cardiac adverse events and may improve survival in selected patients. Further studies should refine patient selection and assess long-term outcomes.</div></div>","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"50 7","pages":"Article 103057"},"PeriodicalIF":3.0,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143903975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Histone modifications as molecular drivers of cardiac aging: Metabolic alterations, epigenetic mechanisms, and emerging therapeutic strategies","authors":"Faris Alrumaihi ,&nbsp;Amin A. Al-Doaiss ,&nbsp;Faqir Ullah ,&nbsp;Wanian M. Alwanian ,&nbsp;Hajed Obaid Alharbi ,&nbsp;Fai Abdullah Alassaf ,&nbsp;Somayah Mohammad Alfifi ,&nbsp;Fahad M Alshabrmi ,&nbsp;Faris F. Aba Alkhay ,&nbsp;Eid A. Alatawi","doi":"10.1016/j.cpcardiol.2025.103056","DOIUrl":"10.1016/j.cpcardiol.2025.103056","url":null,"abstract":"<div><div>Cardiac aging represents a complex pathophysiological process characterized by progressive metabolic recombination and functional dedifferentiation of cardiac cellular components. Despite advancements in cardiovascular medicine, a critical research gap persists in understanding the precise epigenetic mechanisms that drive age-related cardiac dysfunction. This comprehensive review elucidates the pivotal role of histone modifications—including methylation, acetylation, and phosphorylation—in orchestrating the molecular landscape of cardiac aging. Significant gaps remain in our understanding of site-specific histone modification impacts on cardiac function, the intricate crosstalk between different histone marks, and their integration with metabolic alterations that characterize the aging myocardium. Current evidence reveals a dynamic epigenetic signature in aged cardiac tissue, typically featuring increased transcriptional activation markers alongside decreased repressive marks, though context-dependent variations exist. This review explores how histone modifications influence critical pathways governing mitochondrial dysfunction, DNA damage repair, inflammation, and fibrosis in aging hearts. Innovative therapeutic approaches targeting specific histone-modifying enzymes promise to mitigate age-related cardiac deterioration, potentially revolutionizing treatment paradigms for cardiovascular diseases in aging populations. Addressing these knowledge gaps requires multidimensional approaches that integrate epigenomics with functional assessment of cardiac performance.</div></div>","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"50 7","pages":"Article 103056"},"PeriodicalIF":3.0,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143912269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editor’s Message","authors":"","doi":"10.1016/S0146-2806(25)00072-6","DOIUrl":"10.1016/S0146-2806(25)00072-6","url":null,"abstract":"","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"50 5","pages":"Article 103050"},"PeriodicalIF":3.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143738789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}